ClinicalTrials.gg
CompletedNCT05053126Updated Aug 14, 2023Results posted

Study Evaluating Abuse Potential of Lyrica® in Healthy Non-Drug Dependent Recreational Opioid Users

A Phase 4 interventional study of Pregabalin 300mg and pregabalin 450 mg in Abuse Potential, sponsored by Viatris Specialty LLC. Completed at 1 site in United States. Open to participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2023-08-14.

Sponsored by Viatris Specialty LLC (part of Viatris Inc.) · Phase 4, Interventional, and Other

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
60
Allocation
Randomized
Ages
18 Years to 55 Years
Sex
All
01

Study summary

This is a Phase 4 clinical study in healthy non-drug dependent recreational opioid users to assess the abuse potential of Lyrica when taken alone or in combination with oxycodone.

Read the detailed description

This is a randomized, double-blind, double-dummy, placebo- and active-controlled, 6-treatment, 6-period crossover, single-dose study in healthy male and/or female adult, non drug-dependent recreational opioid users. The study includes Screening, a Qualification Phase, a Treatment Phase and Follow-up. This study will randomize approximately 60 adult male and female (at least 20% female) participants (10 participants in each sequence) in the Treatment Phase to ensure at least 48 participants complete the Treatment Phase of the study. There will be 8 visits to the clinic in total and a follow-up telephone call at the end of the study. The duration of participation will be approximately 16 weeks and 7 of the visits will involve clinic stays of 4 days/3 nights.

02

Conditions studied

  • Abuse Potential

Keywords

  • Lyrica
  • Pregabalin
  • Oxycodone
  • Opioid
  • Abuse liability
03

In context

Lead sponsor

Viatris Specialty LLC is the lead sponsor of 5 studies on the registry; none are open to participants now.

Of its 5 completed or terminated interventional studies of FDA-regulated products, 3 (60%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Male and female participants must be 18 to 55 years of age, inclusive, at the time of screening. There must be no less than 20% female participants in the Treatment Phase.
  2. Male and female participants who are overtly healthy. Healthy is defined as no abnormalities identified by a detailed medical history, full physical examination, vital signs, 12-lead , and/or clinical laboratory tests.
  3. Participants must have drug abuse experience with opioids; ie, must have used opioids for non-therapeutic purposes (ie, for psychoactive effects) on at least 10 occasions within the last year and at least once in the 8 weeks before the Screening Visit (Visit 1).
  4. Participants must satisfactorily complete both the Naloxone Challenge and the Drug Discrimination.
  5. Participants who are willing and able to comply with all scheduled visits, treatment plan, laboratory tests, lifestyle considerations, and other study procedures.
  6. (BMI) of 17.5 to 34 kg/m2, inclusive; and a total body weight

    ≥50 kg (110 lb).

  7. Capable of giving signed , which includes compliance with the requirements and restrictions listed in the informed consent document (ICD).

Exclusion criteria

Exclusion Criteria:

  1. Current or past diagnosis of any type of drug dependence within the past year. Diagnosis of substance and/or alcohol dependence (excluding caffeine and nicotine) will be assessed by the Investigator using the Diagnostic and Statistical Manual-4 (DSM-4) criteria performed at Screening. Current drug use will be allowed if the candidate can produce a negative urine sample and are free of any signs/symptoms of withdrawal. The candidate will be informed if they have a positive breathalyzer test.
  2. Evidence or history of hematological, renal, endocrine, pulmonary, gastrointestinal, cardiovascular, hepatic, psychiatric, neurological, or allergic disease (including drug allergies, but excluding untreated, asymptomatic, seasonal allergies at the time of dosing).
  3. Any condition possibly affecting drug absorption (eg, gastrectomy) excluding cholecystectomy within 1 year prior to study.
  4. Abnormal baseline EtCO2 \<35mm Hg or >45 mm Hg.
  5. Clinical or laboratory evidence of active hepatitis A infection or a history of (HIV) infection, , or and/or positive testing for HIV, hepatitis B surface antigen (HBsAg), hepatitis B core antibody (HBcAb), or hepatitis C antibody (HCVAb).
  6. Participants with active suicidal ideation or suicidal behavior within 5 year prior to Screening as determined through the use of the Columbia-Suicide Severity Rating Scale (C-SSRS) or active ideation identified at Screening or on Day 0.
  7. Other acute or chronic medical or psychiatric condition including recent (within the past year) or active suicidal ideation or behavior or laboratory abnormality that may increase the risk associated with study participation or product administration or may interfere with the interpretation of study results and, in the judgment of the investigator, would make the participant inappropriate for entry into this study.
  8. Patients with: sleep apnea, myasthenia gravis and glaucoma.
  9. Use of prescription or nonprescription drugs and dietary supplements within 7 days or 5 half-lives (whichever is longer) prior to the first dose of investigational product.
  10. Herbal supplements and herbal medications must be discontinued at least 28 days prior to the first dose of study medication.
  11. Previous administration with an investigational drug within 30 days (or as determined by the local requirement) or 5 half-lives (whichever is longer) preceding the first dose of investigational product used in this study.
  12. Positive urine drug screen (UDS) for substances of abuse at each admission in the Qualification and Treatment Phase, excluding tetrahydrocannabinol (THC). If a participant presents with a positive UDS excluding THC at any admission or any visit, the investigator, at his/her discretion, may reschedule a repeat of UDS until the UDS is negative, excluding THC, before the participant is permitted to participate in any phase of the study.
  13. Unable to abstain from using THC during the Qualification and Treatment Phase of the study.
  14. Has participated in, is currently participating in, or is seeking treatment for substance-and/or alcohol-related disorders (excluding nicotine and caffeine).
  15. Has a positive alcohol breathalyzer or urine test at each admission to the study center during qualification and treatment phase. Positive results may be repeated and/or participants re-scheduled at the Investigator's discretions.
  16. Participants are heavy smokers or users of other types of nicotine products (>20 cigarettes equivalents per day).
  17. Participants are unable to abstain from smoking for at least 2 hours before and at least 8 hours after study drug administration.
  18. Screening sitting blood pressure (BP) ≥140 mm Hg (systolic) or ≥90 mm Hg (diastolic), following at least 5 minutes rest. If BP is ≥140 mm Hg (systolic) or

    ≥90 mm Hg (diastolic), the BP should be repeated 2 more times and the average of the 3 BP values should be used to determine the participant's eligibility. Repeated BP tests should be spaced at least 5 minutes apart.

  19. Baseline (screening) 12-lead (ECG) that demonstrates clinically relevant abnormalities that may affect participant safety or interpretation of study results (eg, baseline (QTc) interval as determined by the Fridericia method (QTcF) >450 msec, complete left bundle branch block [LBBB], signs of an acute or indeterminate-age myocardial infarction, ST-T interval changes suggestive of myocardial ischemia, second- or third-degree atrioventricular [AV] block, or serious bradyarrhythmias or tachyarrhythmias). If the baseline uncorrected QT interval is >450 msec, this interval should be rate-corrected using the Fridericia method and the resulting QTcF should be used for decision making and reporting. If QTcF exceeds 450 msec, or QRS exceeds 120 msec, the ECG should be repeated 2 more times and the average of the 3 QTcF or QRS values should be used to determine the participant's eligibility. Computer-interpreted ECGs should be overread by a physician experienced in reading ECGs before excluding participants.
  20. Participants with ANY of the following abnormalities in clinical laboratory tests at screening, as assessed by the study-specific laboratory and confirmed by a single repeat test, if deemed necessary: (AST) or alanine aminotransferase (ALT) level 1.5 × (ULN); Total level ≥1.5 × ULN; participants with a history of Gilbert's syndrome may have direct bilirubin measured and would be eligible for this study provided the direct bilirubin level is ≤ ULN.
  21. Blood donation (excluding plasma donations) of approximately 1 pint (500 mL) or more within 60 days prior to dosing.
  22. History of sensitivity to heparin or heparin-induced thrombocytopenia.
  23. Unwilling or unable to comply with the criteria in the Lifestyle Considerations section of this protocol.
  24. History of to pregabalin or oxycodone or any of the components in the formulation of the study products.
  25. Investigator site staff members directly involved in the conduct of the study and their family members, site staff members otherwise supervised by the investigator, or Sponsor employees, including their family members, directly involved in the conduct of the study.
Terms in these criteria, in plain language(13)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 4
Primary purpose
Other
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Triple (Participant, Investigator, Outcomes assessor)
Enrollment
60 participants (actual)

Study arms

  • Experimental
    Lyrica 300 mg

    Single Dose

    Drug: Pregabalin 300mg

  • Experimental
    Lyrica 450 mg

    Single Dose

    Drug: pregabalin 450 mg

  • Experimental
    Lyrica 300mg with Oxycodone 20 mg

    Single Dose

    Drug: Pregabalin 300 mg with oxycodone 20 mg

  • Experimental
    Lyrica 450 mg with Oxycodone 20 mg

    Single Dose

    Drug: pregabalin 450 mg with oxycodone 20 mg

  • Active comparator
    Oxycodone 20 mg

    Single Dose

    Drug: oxycodone 20 mg

  • Placebo comparator
    Placebo

    Single Dose

    Drug: Placebo

Interventions

  • Participant will receive an oral dose of pregabalin 300 mg

  • Participant will receive an oral dose of pregabalin 450 mg

  • DrugPregabalin 300 mg with oxycodone 20 mg

    Drug page: Pregabalin

    Participant will receive an oral dose of pregabalin 300 mg and oxycodone 20 mg

  • Drugpregabalin 450 mg with oxycodone 20 mg

    Drug page: Pregabalin

    Participant will receive an oral dose of pregabalin 450 mg and oxycodone 20 mg

  • Participant will receive an oral dose of oxycodone 20 mg

  • DrugPlacebo

    Participant will receive an oral dose of placebo

06

What researchers measure

Primary outcomes

  1. Bipolar Visual Analog Scale (VAS) for "Drug Liking" Maximum Effect (Emax).

    Drug liking assesses how much a participant likes or dislikes a drug effect at the time the question ("at this moment, my liking this drug is") is being asked. It is scored using a 100 mm visual analogue scale (VAS), where 0 mm = "Strong Disliking", 50 mm = "Neither Like nor Dislike", and 100 mm = "Strong Liking"

    Time frame: up to 48 hours after treatment

Secondary outcomes

  1. Unipolar VAS for "High" - Maximum Effect (Emax)

    Maximum effect on the 100 mm visual analog scale for the question "I am feeling high" where 0 = "not at all" and 100 = "extremely"

    Time frame: up to 48 hours after treatment

  2. Bipolar VAS for "Take Drug Again"

    100 mm visual analog scale at 24, 36, and 48 hours post-dose for the question "I would take this drug again" where 0 = "definitely not", 50 = "neutral", and 100 = "definitely so". The data from the 24, 36, and 48 hours postdose measurements were combined into a single overall model-adjusted value for 24 to 48 hours post-treatment timeframe by estimation from a mixed model with treatment, period, treatment sequence, time, and treatment\*time as fixed effects, subject nested within sequence as a random effect. The compound symmetric covariance matrix was employed. Data from all time points were included

    Time frame: Up to 48 hours after treatment (assessments were made at the following timepoints after each treatment for this outcome measure: 24, 36, and 48 hours)

  3. Bipolar VAS for "Overall Drug Liking"

    100 mm visual analog scale at 24, 36, and 48 hours post-dose for the question "Overall, my liking for this drug is" where 0 = "definitely not", 50 = "neutral", and 100 = "definitely so". The data from the 24, 36, and 48 hours postdose measurements were combined into a single overall model-adjusted value for 24 to 48 hours post-treatment timeframe by estimation from a mixed model with treatment, period, treatment sequence, time, and treatment\*time as fixed effects, subject nested within sequence as a random effect. The compound symmetric covariance matrix was employed. Data from all time points were included

    Time frame: Up to 48 hours after treatment (assessments were made at the following timepoints after each treatment for this outcome measure: 24, 36, and 48 hours)

  4. Unipolar VAS for "Any Drug Effect"

    100 mm visual analog scale for the question "At this moment, I can feel any drug effects" where 0 = "not at all" and 100 = "extremely"

    Time frame: up to 48 hours after treatment

07

Results

Posted Aug 14, 2023

Participant flow

Participant flow — Overall Study
MilestoneSequence 1Sequence 2Sequence 3Sequence 4Sequence 5Sequence 6
Started101010101010
Completed1010109109
Not completed000101

Outcome measures

PrimaryBipolar Visual Analog Scale (VAS) for "Drug Liking" Maximum Effect (Emax).

Drug liking assesses how much a participant likes or dislikes a drug effect at the time the question ("at this moment, my liking this drug is") is being asked. It is scored using a 100 mm visual analogue scale (VAS), where 0 mm = "Strong Disliking", 50 mm = "Neither Like nor Dislike", and 100 mm = "Strong Liking"

Time frame:
up to 48 hours after treatment
Reported as:
Mean · Score on a 100 mm scale
Bipolar Visual Analog Scale (VAS) for "Drug Liking" Maximum Effect (Emax).
Score on a 100 mm scalePlaceboOxycodone 20 mgLyrica 300 mgLyrica 450 mgLyrica 300mg With Oxycodone 20 mgLyrica 450 mg With Oxycodone 20 mg
Bipolar Visual Analog Scale (VAS) for "Drug Liking" Maximum Effect (Emax).54.30 ± 1.78690.85 ± 2.49372.53 ± 3.22476.05 ± 3.15196.11 ± 1.55995.06 ± 1.885
Statistical analysis
  • Placebo vs Oxycodone 20 mg · Mixed Models Analysis · p = <0.0001 · Mean difference (final values): 36.83
  • Placebo vs Oxycodone 20 mg vs Lyrica 300mg With Oxycodone 20 mg · Mixed Models Analysis · p = 0.2469 · Mean difference (final values): -2.4
  • Placebo vs Oxycodone 20 mg vs Lyrica 450 mg With Oxycodone 20 mg · Mixed Models Analysis · p = 0.1756 · Mean difference (final values): -3.3
  • Oxycodone 20 mg vs Lyrica 300 mg · Mixed Models Analysis · p = 0.0001 · Mean difference (final values): -0.4
  • Oxycodone 20 mg vs Lyrica 450 mg · Mixed Models Analysis · p = 0.0099 · Mean difference (final values): 3.3
  • Placebo vs Lyrica 300 mg · Mixed Models Analysis · p = 0.9888 · Mean difference (final values): 18.2
  • Placebo vs Lyrica 450 mg · Mixed Models Analysis · p = 0.9997 · Mean difference (final values): 22.0
SecondaryUnipolar VAS for "High" - Maximum Effect (Emax)

Maximum effect on the 100 mm visual analog scale for the question "I am feeling high" where 0 = "not at all" and 100 = "extremely"

Time frame:
up to 48 hours after treatment
Reported as:
Mean · Score on a 100 mm scale
Unipolar VAS for "High" - Maximum Effect (Emax)
Score on a 100 mm scalePlaceboOxycodone 20 mgLyrica 300 mgLyrica 450 mgLyrica 300mg With Oxycodone 20 mgLyrica 450 mg With Oxycodone 20 mg
Unipolar VAS for "High" - Maximum Effect (Emax)10.83 ± 4.02085.83 ± 4.33355.83 ± 6.18060.43 ± 5.80191.36 ± 3.23792.23 ± 3.264
Statistical analysis
  • Placebo vs Oxycodone 20 mg · Mixed Models Analysis · p = <0.0001 · Mean difference (final values): 75.60 · 90% CI 65.79 to 85.42
  • Placebo vs Lyrica 300 mg · Mixed Models Analysis · p = <0.0001 · Mean difference (final values): 44.84 · 90% CI 35.03 to 54.65
  • Placebo vs Lyrica 450 mg · Mixed Models Analysis · p = <0.0001 · Mean difference (final values): 49.93 · 90% CI 40.12 to 59.75
  • Placebo vs Lyrica 300mg With Oxycodone 20 mg · Mixed Models Analysis · p = <0.0001 · Mean difference (final values): 80.80 · 90% CI 70.99 to 90.61
  • Placebo vs Lyrica 450 mg With Oxycodone 20 mg · Mixed Models Analysis · p = <0.0001 · Mean difference (final values): 81.91 · 90% CI 72.09 to 91.73
  • Oxycodone 20 mg vs Lyrica 300 mg · Mixed Models Analysis · p = <0.0001 · Mean difference (final values): -30.8 · 90% CI -40.6 to -20.9
  • Oxycodone 20 mg vs Lyrica 450 mg · Mixed Models Analysis · p = <0.0001 · Mean difference (final values): -25.7 · 90% CI -35.5 to -15.9
  • Oxycodone 20 mg vs Lyrica 300mg With Oxycodone 20 mg · Mixed Models Analysis · p = 0.3829 · Mean difference (final values): 5.20 · 90% CI -4.62 to 15.01
  • Oxycodone 20 mg vs Lyrica 450 mg With Oxycodone 20 mg · Mixed Models Analysis · p = 0.2896 · Mean difference (final values): 6.31 · 90% CI -3.50 to 16.11
SecondaryBipolar VAS for "Take Drug Again"

100 mm visual analog scale at 24, 36, and 48 hours post-dose for the question "I would take this drug again" where 0 = "definitely not", 50 = "neutral", and 100 = "definitely so". The data from the 24, 36, and 48 hours postdose measurements were combined into a single overall model-adjusted value for 24 to 48 hours post-treatment timeframe by estimation from a mixed model with treatment, period, treatment sequence, time, and treatment\*time as fixed effects, subject nested within sequence as a random effect. The compound symmetric covariance matrix was employed. Data from all time points were included

Time frame:
Up to 48 hours after treatment (assessments were made at the following timepoints after each treatment for this outcome measure: 24, 36, and 48 hours)
Reported as:
Least squares mean · Score on a 100 mm scale
Bipolar VAS for "Take Drug Again"
Score on a 100 mm scalePlaceboOxycodone 20 mgLyrica 300 mgLyrica 450 mgLyrica 300mg With Oxycodone 20 mgLyrica 450 mg With Oxycodone 20 mg
Bipolar VAS for "Take Drug Again"53.58 ± 2.66477.05 ± 2.66863.98 ± 2.66164.87 ± 2.66977.91 ± 2.67475.92 ± 2.664
Statistical analysis
  • Placebo vs Oxycodone 20 mg · Mixed Models Analysis · p = <0.0001 · Mean difference (final values): 23.47 · 90% CI 19.77 to 27.17
  • Placebo vs Lyrica 300 mg · Mixed Models Analysis · p = <0.0001 · Mean difference (final values): 10.40 · 90% CI 6.71 to 14.09
  • Placebo vs Lyrica 450 mg · Mixed Models Analysis · p = <0.0001 · Mean difference (final values): 11.29 · 90% CI 7.59 to 14.99
  • Placebo vs Lyrica 300mg With Oxycodone 20 mg · Mixed Models Analysis · p = <0.0001 · Mean difference (final values): 24.33 · 90% CI 20.62 to 28.03
  • Placebo vs Lyrica 450 mg With Oxycodone 20 mg · Mixed Models Analysis · p = <0.0001 · Mean difference (final values): 22.34 · 90% CI 18.65 to 26.04
  • Oxycodone 20 mg vs Lyrica 300 mg · Mixed Models Analysis · p = <0.0001 · Mean difference (final values): -13.1 · 90% CI -16.8 to -9.38
  • Oxycodone 20 mg vs Lyrica 450 mg · Mixed Models Analysis · p = <0.0001 · Mean difference (final values): -12.2 · 90% CI -15.9 to -8.47
  • Oxycodone 20 mg vs Lyrica 300mg With Oxycodone 20 mg · Mixed Models Analysis · p = 0.7051 · Mean difference (final values): 0.86 · 90% CI -2.86 to 4.57
  • Oxycodone 20 mg vs Lyrica 450 mg With Oxycodone 20 mg · Mixed Models Analysis · p = 0.6160 · Mean difference (final values): -1.13 · 90% CI -4.82 to 2.57
SecondaryBipolar VAS for "Overall Drug Liking"

100 mm visual analog scale at 24, 36, and 48 hours post-dose for the question "Overall, my liking for this drug is" where 0 = "definitely not", 50 = "neutral", and 100 = "definitely so". The data from the 24, 36, and 48 hours postdose measurements were combined into a single overall model-adjusted value for 24 to 48 hours post-treatment timeframe by estimation from a mixed model with treatment, period, treatment sequence, time, and treatment\*time as fixed effects, subject nested within sequence as a random effect. The compound symmetric covariance matrix was employed. Data from all time points were included

Time frame:
Up to 48 hours after treatment (assessments were made at the following timepoints after each treatment for this outcome measure: 24, 36, and 48 hours)
Reported as:
Least squares mean · Score on a 100 mm scale
Bipolar VAS for "Overall Drug Liking"
Score on a 100 mm scalePlaceboOxycodone 20 mgLyrica 300 mgLyrica 450 mgLyrica 300mg With Oxycodone 20 mgLyrica 450 mg With Oxycodone 20 mg
Bipolar VAS for "Overall Drug Liking"53.74 ± 2.76275.73 ± 2.76660.14 ± 2.76063.54 ± 2.76774.86 ± 2.77275.01 ± 2.762
Statistical analysis
  • Placebo vs Oxycodone 20 mg · Mixed Models Analysis · p = <0.0001 · Mean difference (final values): 21.99 · 90% CI 18.31 to 25.67
  • Placebo vs Lyrica 300 mg · Mixed Models Analysis · p = 0.0042 · Mean difference (final values): 6.40 · 90% CI 2.73 to 10.07
  • Placebo vs Lyrica 450 mg · Mixed Models Analysis · p = <0.0001 · Mean difference (final values): 9.80 · 90% CI 6.12 to 13.48
  • Placebo vs Lyrica 300mg With Oxycodone 20 mg · Mixed Models Analysis · p = <0.0001 · Mean difference (final values): 21.12 · 90% CI 17.44 to 24.81
  • Placebo vs Lyrica 450 mg With Oxycodone 20 mg · Mixed Models Analysis · p = <0.0001 · Mean difference (final values): 21.27 · 90% CI 17.59 to 24.95
  • Oxycodone 20 mg vs Lyrica 300 mg · Mixed Models Analysis · p = <0.0001 · Mean difference (final values): -15.6 · 90% CI -19.3 to -11.9
  • Oxycodone 20 mg vs Lyrica 450 mg · Mixed Models Analysis · p = <0.0001 · Mean difference (final values): -12.2 · 90% CI -15.9 to -8.50
  • Oxycodone 20 mg vs Lyrica 300mg With Oxycodone 20 mg · Mixed Models Analysis · p = 0.7001 · Mean difference (final values): -0.87 · 90% CI -4.56 to 2.83
  • Oxycodone 20 mg vs Lyrica 450 mg With Oxycodone 20 mg · Mixed Models Analysis · p = 0.7479 · Mean difference (final values): -0.72 · 90% CI -4.40 to 2.96
SecondaryUnipolar VAS for "Any Drug Effect"

100 mm visual analog scale for the question "At this moment, I can feel any drug effects" where 0 = "not at all" and 100 = "extremely"

Time frame:
up to 48 hours after treatment
Reported as:
Least squares mean · Score on a 100 mm scale
Unipolar VAS for "Any Drug Effect"
Score on a 100 mm scalePlaceboOxycodone 20 mgLyrica 300 mgLyrica 450 mgLyrica 300mg With Oxycodone 20 mgLyrica 450 mg With Oxycodone 20 mg
Unipolar VAS for "Any Drug Effect"2.14 ± 2.07629.97 ± 2.07516.68 ± 2.07320.00 ± 2.07536.55 ± 2.07540.98 ± 2.075
Statistical analysis
  • Placebo vs Oxycodone 20 mg · Mixed Models Analysis · p = <0.0001 · Mean difference (final values): 27.82 · 90% CI 25.45 to 30.19
  • Placebo vs Lyrica 300 mg · Mixed Models Analysis · p = <0.0001 · Mean difference (final values): 14.53 · 90% CI 12.17 to 16.89
  • Placebo vs Lyrica 450 mg · Mixed Models Analysis · p = <0.0001 · Mean difference (final values): 17.85 · 90% CI 15.49 to 20.22
  • Placebo vs Lyrica 300mg With Oxycodone 20 mg · Mixed Models Analysis · p = <0.0001 · Mean difference (final values): 34.40 · 90% CI 34.40 to 36.77
  • Placebo vs Lyrica 450 mg With Oxycodone 20 mg · Mixed Models Analysis · p = <0.0001 · Mean difference (final values): 38.84 · 90% CI 36.47 to 41.21
  • Oxycodone 20 mg vs Lyrica 300 mg · Mixed Models Analysis · p = <0.0001 · Mean difference (final values): -13.3 · 90% CI -15.6 to -10.9
  • Oxycodone 20 mg vs Lyrica 450 mg · Mixed Models Analysis · p = <0.0001 · Mean difference (final values): -9.97 · 90% CI -12.3 to -7.61
  • Oxycodone 20 mg vs Lyrica 300mg With Oxycodone 20 mg · Mixed Models Analysis · p = <0.0001 · Mean difference (final values): 6.58 · 90% CI 4.22 to 8.94
  • Oxycodone 20 mg vs Lyrica 450 mg With Oxycodone 20 mg · Mixed Models Analysis · p = <0.0001 · Mean difference (final values): 11.02 · 90% CI 8.65 to 13.38

Adverse events

Collected over During the entire Treatment Phase of the study, which encompassed the time interval from admission of the subject to their first Treatment Period until 28 days after study drug dosing in their last (6th) Treatment Period, including the washout in between Treatment Periods. The total duration of the Treatment Phase for each subject was dependent on visit scheduling and whether the subject completed all 6 treatment periods, and it lasted up to approximately 13 weeks.. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Placebo0/58 (0%)0/58 (0%)2/58 (3.4%)
Oxycodone 20 mg0/58 (0%)0/58 (0%)9/58 (15.5%)
Lyrica 300 mg0/58 (0%)0/58 (0%)1/58 (1.7%)
Lyrica 450 mg0/59 (0%)0/59 (0%)4/59 (6.8%)
Lyrica 300mg With Oxycodone 20 mg0/59 (0%)0/59 (0%)4/59 (6.8%)
Lyrica 450 mg With Oxycodone 20 mg0/59 (0%)0/59 (0%)8/59 (13.6%)
Most frequent other events
Most frequent other events
EventPlaceboOxycodone 20 mgLyrica 300 mgLyrica 450 mgLyrica 300mg With Oxycodone 20 mgLyrica 450 mg With Oxycodone 20 mg
NauseaGastrointestinal disorders0/585/580/581/592/595/59
COVID-19Infections and infestations1/583/580/581/590/593/59
HeadacheNervous system disorders1/583/580/580/591/590/59
VomitingGastrointestinal disorders0/581/580/581/593/593/59
Atrial fibrillationCardiac disorders0/581/581/580/590/590/59
Dental cariesGastrointestinal disorders0/580/580/581/590/590/59
DizzinessNervous system disorders0/580/580/581/590/590/59
HypotensionVascular disorders0/580/580/581/590/590/59

Baseline characteristics

The randomized population included all participants who were randomized to a treatment sequence in the Treatment Phase

Age, Continuous
Age, Continuous(Years)Randomized Population
Mean32.8 ± 8.51
Sex: Female, Male
Sex: Female, Male(Participants)Randomized Population
Female13
Male47
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Randomized Population
Hispanic or Latino17
Not Hispanic or Latino43
Unknown or Not Reported0
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Randomized Population
American Indian or Alaska Native1
Asian0
Native Hawaiian or Other Pacific Islander0
Black or African American38
White19
More than one race2
Unknown or Not Reported0
Region of Enrollment
Region of Enrollment(participants)Randomized Population
United States60
08

Study locations

1 site
  • Hassman Research Institute
    Marlton, New Jersey 08053, United States
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jul 2021 to primary completion in Apr 2022, 8 months.

Results were first posted in Aug 2023, 1 year 4 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 13, 2021
First posted
Sep 22, 2021
StartActual
Jul 27, 2021
Primary completionActual
Apr 1, 2022
CompletionActual
Apr 1, 2022
Results first posted
Aug 14, 2023
Last update
Aug 14, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 14, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT05053126
Responsible party
Sponsor
First posted
Sep 22, 2021
Start date
Jul 27, 2021
Primary completion
Apr 1, 2022
Completion
Apr 1, 2022
Results posted
Aug 14, 2023
Last update
Aug 14, 2023

Study contacts

Dik WH Ng, PhD
study director · Mylan Pharmaceutials

Oversight

FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Pregabalin

Start the discussion